Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency
Ellina Lytvyak, Arshdeep Rattol, Eduardo Grunvald · 2026
Read Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency by Ellina Lytvyak, Arshdeep Rattol, Eduardo Grunvald (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13535729.txt.
Description
Lytvyak, Rattol, and Grunvald report a single case of a woman with severe obesity tied to a partial gene defect, treated with a hormone pathway drug. The drug, setmelanotide, is known for rare genetic obesity where the gene is fully broken. This patient carried one faulty copy, had early onset obesity, and had responded poorly to surgery and standard drugs. Their report was published in 2026.
Over three months on the drug, she lost 11.8 percent of her body weight. Lab work suggests her gene variant cuts enzyme function by only ten to thirty percent, yet the drug worked strongly. She also developed severe skin darkening, a side effect the authors call a first for this gene type. They read the case as support for wider use, with care.
Catalog record
| CREATOR | Ellina Lytvyak, Arshdeep Rattol, Eduardo Grunvald |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |